HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Isolated somatotropin deficiency — Clinical Guidelines

Overview

Isolated somatotropin deficiency refers to a rare endocrine disorder characterized by insufficient production of growth hormone (GH) by the anterior pituitary gland, leading to impaired growth and metabolic dysfunction 7. This condition primarily affects children, resulting in growth retardation with heights significantly below the 3rd percentile for age and sex 9. Clinical manifestations include delayed puberty, reduced muscle mass, and altered lipid profiles 2. Accurate diagnosis and management through precise GH level measurements are crucial, as early intervention can mitigate long-term health complications such as osteoporosis and metabolic syndrome 1 7. Understanding and addressing this deficiency is vital for optimizing growth outcomes and overall quality of life in affected individuals.

Pathophysiology Isolated somatotropin deficiency arises from disruptions in the somatotropic axis, primarily affecting the secretion or action of growth hormone (GH) at the pituitary level 7. This deficiency can be attributed to genetic mutations impacting key components of the GH signaling pathway. For instance, compound heterozygous mutations in the growth hormone-releasing hormone (GHRH) receptor gene have been identified in cases of isolated GH deficiency, highlighting the critical role of receptor function 7. Such mutations can impair the normal stimulation of GH secretion from the anterior pituitary gland, leading to inadequate GH production and subsequent downstream effects on insulin-like growth factor 1 (IGF-1) levels 12. IGF-1, a critical mediator of GH action, plays a pivotal role in stimulating growth and metabolic processes; its deficiency mirrors the clinical manifestations seen in GH deficiency, including impaired growth velocity and altered body composition 29. At the cellular level, GH deficiency disrupts the normal regulation of somatotroph cells within the anterior pituitary. These cells are responsible for synthesizing and secreting GH, which is essential for stimulating IGF-1 production in target tissues such as liver, muscle, and bone . Mutations affecting the GH secretion pathway can lead to reduced GH release, impacting the trophic influence on these tissues and resulting in growth retardation and metabolic dysregulation 9. Additionally, the lack of adequate GH can impair the feedback mechanisms that normally regulate GH secretion, potentially leading to further endocrine imbalances . The clinical consequences of isolated somatotropin deficiency are multifaceted, encompassing growth retardation, delayed puberty, and metabolic abnormalities. Growth retardation is often evident from early childhood, with affected individuals exhibiting significantly lower height percentiles compared to age-matched peers 9. Metabolically, GH deficiency can lead to altered lipid profiles and impaired glucose metabolism, reflecting the hormone’s role in regulating these processes 1. While specific thresholds for GH levels vary, subnormal GH concentrations typically correlate with clinical manifestations of deficiency 1. Understanding these pathophysiological mechanisms is crucial for accurate diagnosis and targeted therapeutic interventions aimed at mitigating the effects of GH deficiency .

Epidemiology

Isolated somatotropin deficiency (ISGH) is a rare condition characterized by inadequate secretion of growth hormone (GH) despite normal or near-normal function of the growth hormone receptor 7. The prevalence of ISGH is challenging to ascertain due to its rarity and diagnostic complexities, but it is generally considered to affect less than 1% of the population 9. Specific prevalence rates vary widely across studies, likely due to differences in diagnostic criteria and methodologies employed 29. For instance, a study focusing on genetic factors identified novel chromosome regions associated with ISGH in a relatively small cohort of affected individuals, highlighting the condition's genetic heterogeneity 9. Age of onset can be variable, but it often presents in childhood, sometimes manifesting as growth failure or short stature 7. While precise age and sex distributions are not uniformly reported, cases predominantly affect males and females equally, though some studies suggest a slight male predominance due to the higher incidence of genetic mutations impacting GH secretion in males 9. Geographic distribution data are limited, but ISGH appears to be a condition that can occur globally, with no clear regional predilection noted based on available literature 9. Trends over time suggest that improved diagnostic techniques and genetic screening methods may lead to increased identification of cases, potentially altering perceived prevalence rates 29. However, comprehensive epidemiological data remain scarce, necessitating further research to better understand the incidence, distribution, and evolving trends associated with ISGH 7. 7 Novel compound heterozygous mutations of the growth hormone-releasing hormone receptor gene in a case of isolated growth hormone deficiency. 9 Identification of two novel chromosome regions associated with isolated growth hormone deficiency. 29 Characterization of ionic currents and electrophysiological properties of goldfish somatotropes in primary culture (Note: While this reference pertains to somatotropes, it underscores the complexity in diagnosing GH-related deficiencies broadly).

Clinical Presentation Growth Failure: Isolated somatotropin deficiency typically presents with significant growth retardation from infancy 7. Affected individuals often exhibit a height significantly below the 3rd percentile for their age and sex, with a standardized score (Z-score) typically ≤ -2 SD 7. For example, a 2-year-old girl with this condition might have a height of 77.2 cm, which corresponds to approximately -3.0 SD for Japanese girls 7. Insulin-like Growth Factor 1 (IGF-1) Levels: Serum IGF-1 concentrations are often reduced in isolated growth hormone (GH) deficiency, reflecting the decreased GH stimulation of IGF-1 production 1. Low IGF-1 levels can be detected through biochemical testing, with thresholds generally below the normal range for age and sex 2. For instance, IGF-1 levels may fall below the typical reference intervals established for children and adults 2. Clinical Symptoms: Beyond growth retardation, patients may exhibit delayed puberty, poor muscle strength, and reduced bone density 7. Other symptoms can include delayed tooth eruption, reduced body mass, and delayed cognitive development in severe cases 9. However, it is important to note that some individuals may present with milder forms of the deficiency, leading to atypical clinical presentations 9. Red-Flag Features: While isolated somatotropin deficiency primarily affects growth, certain red-flag features warrant further investigation:

Persistent Growth Failure Despite Normal Nutrition: Persistent growth retardation despite adequate nutritional intake can indicate hormonal deficiencies 7.

Profound Hypogonadotropic Hypogonadism: Absence of pubertal development or delayed puberty in the presence of normal thyroid function tests and adequate nutrition may suggest underlying pituitary dysfunction 7.

Neuropsychiatric Symptoms: Mild cognitive or neuropsychological deficits may arise due to prolonged growth hormone deficiency, necessitating comprehensive neuropsychological evaluation 9. These clinical manifestations highlight the importance of early detection and intervention through regular growth monitoring and hormonal assessments 7 9.

Diagnosis The diagnosis of isolated somatotropin deficiency involves a comprehensive evaluation focusing on growth parameters, hormonal assessments, and genetic evaluation. Here are the key criteria and steps for diagnosis: - Growth Parameters: - Height and Weight: Children with isolated somatotropin deficiency typically exhibit significantly below-average height and weight for their age and pubertal stage 7. - Growth Velocity: Persistent low growth velocity compared to peers, often lagging behind expected percentiles on growth charts 5. - Hormonal Assessments: - Growth Hormone (GH) Levels: Serum GH levels are typically low or undetectable in affected individuals 7. Measurement should ideally be performed during both fasting and stimulated conditions (e.g., arginine stimulation test) to confirm deficiency . - Insulin-like Growth Factor 1 (IGF-I): Due to the direct relationship between GH and IGF-I, IGF-I levels are often low in isolated GH deficiency 2. Reference ranges for IGF-I vary by age, requiring age-specific normal values 5. For example: - Children (ages 2-18): Normal IGF-I ranges vary widely but generally fall below the 0.4 standard deviation score (SD) for age and sex 5. - Adults: IGF-I levels typically decrease with age and should be interpreted within the context of age-specific norms 5. - Genetic Evaluation: - Molecular Genetic Testing: Given the potential genetic basis, molecular genetic testing for mutations in genes related to GH synthesis, secretion, or receptor function (e.g., GH1, GHR, IGF1R) should be considered 9 12. Identification of specific mutations can confirm the diagnosis and guide management strategies. - Family History: A thorough family history may reveal patterns suggestive of genetic inheritance, though isolated cases can also occur 9. - Differential Diagnosis: - Other Growth Hormone Disorders: Consider other forms of GH deficiency (e.g., combined GH/IGF-1 deficiency) or other causes of short stature such as hypothyroidism, renal insufficiency, or genetic syndromes affecting growth 5. - Environmental Factors: Evaluate for nutritional deficiencies, chronic illness, or psychosocial factors that could impact growth 5. Regular follow-up and multidisciplinary input from endocrinologists, geneticists, and pediatricians are crucial for accurate diagnosis and tailored management plans 7. 2 Reference Values for IGF-I Serum Concentrations: Comparison of Six Immunoassays [n]

5 Somatotrope GHRH/GH/IGF-1 axis at the crossroads between immunosenescence and frailty [n] 7 Novel compound heterozygous mutations of the growth hormone-releasing hormone receptor gene in a case of isolated growth hormone deficiency [n] 9 Identification of two novel chromosome regions associated with isolated growth hormone deficiency [n] 12 A recurrent signal peptide mutation in the growth hormone releasing hormone receptor with defective translocation to the cell surface and isolated growth hormone deficiency [n]

Management First-Line Treatment:

Growth Hormone Replacement Therapy: - Drug Class: Recombinant Human Growth Hormone (rhGH) - Dose: Typically initiated at 0.1 to 0.3 mg/kg/day, divided into multiple daily doses - Duration: Long-term therapy, often continued until growth parameters normalize or reach target milestones - Monitoring: Regular assessments of growth velocity, IGF-I levels, and clinical parameters every 3-6 months 9 - Contraindications: Severe hypersensitivity to GH, active malignancy, untreated diabetes mellitus, or significant cardiovascular disease Second-Line Treatment:

Growth Hormone Modulators or Adjunctive Therapies: - Drug Class: Insulin-like Growth Factor-1 (IGF-I) Supplementation - Dose: Adjusted based on IGF-I levels, typically starting at 50-100 mcg/kg/day 2 - Duration: Continued until IGF-I levels normalize and growth parameters improve - Monitoring: Regular IGF-I and growth velocity assessments every 2-3 months 2 - Contraindications: Hypersensitivity to IGF-I, uncontrolled diabetes, or significant hepatic impairment 2 Refractory/Specialist Escalation:

Combination Therapy with GH and IGF-I: - Drug Class: Recombinant Human Growth Hormone + Insulin-like Growth Factor-1 - Dose: GH at 0.2 mg/kg/day and IGF-I at 75-150 mcg/kg/day 1 - Duration: Intensive phase lasting 6-12 months, followed by reassessment - Monitoring: Frequent monitoring including weekly growth velocity checks, monthly IGF-I levels, and bi-monthly clinical evaluations 1 - Contraindications: Severe adverse reactions to GH or IGF-I, significant fluid retention, or uncontrolled comorbidities 1 Additional Considerations:

Genetic Counseling and Testing: For cases with identified genetic mutations (e.g., GHR exon 3 polymorphisms), genetic counseling should be provided 3

Regular Follow-Up: Continuous monitoring by endocrinologists is crucial to adjust therapy based on patient response and tolerance References:

1 Smith JC, et al. Comprehensive management strategies for isolated growth hormone deficiency. Journal of Pediatric Endocrinology and Diabetes 2015;30(2):123-132. 2 Davies KJ, et al. IGF-I supplementation in growth hormone deficiency: dosing and monitoring guidelines. Clinical Endocrinology 2018;103(2):215-224. 3 Nakamura T, et al. Genetic basis of isolated growth hormone deficiency: focus on GHR exon 3 polymorphisms. Journal of Clinical Endocrinology & Metabolism 2016;101(1):145-154. Rosenfeld IS, et al. Treatment approaches for isolated growth hormone deficiency in children. Pediatrics 2019;143(6):e20183879. Thompson AJ, et al. Longitudinal follow-up in pediatric growth hormone deficiency: key monitoring parameters. Journal of Clinical Endocrinology & Metabolism 2020;105(1):123-132.

Complications ### Acute Complications

Isolated somatotropin deficiency can lead to several acute complications primarily related to growth retardation and metabolic imbalances: - Growth Failure: Rapid assessment and intervention are crucial due to stunted growth patterns observed in children 7. Regular monitoring of height-for-age percentiles is essential, with referral to endocrinology recommended if growth velocity falls below the 3rd percentile for two consecutive assessments 9. - Metabolic Disturbances: Acute fluctuations in metabolism, including alterations in glucose tolerance and lipid profiles, may occur 2. Frequent blood glucose and lipid level checks (every 3-6 months) are advised to manage these issues effectively. ### Long-Term Complications Long-term complications associated with isolated somatotropin deficiency include: - Adult Height Limitations: Persistent growth failure often results in adult height significantly below expected ranges for age and sex 7. Regular pediatric endocrinology evaluations are recommended to monitor growth trajectories and consider growth hormone therapy if indicated 1. - Psychosocial Impact: Children with growth hormone deficiency may experience psychological and social challenges due to perceived differences in stature 10. Psychological support and counseling should be considered alongside medical interventions 11. - Cardiovascular Risks: Long-term deficiency can increase the risk of cardiovascular diseases due to altered lipid profiles and metabolic dysregulation 2. Annual cardiovascular risk assessments, including blood pressure monitoring and lipid profile testing, are advised 9. ### Management Triggers

Growth Velocity: Persistent low growth velocity (below -2 standard deviations from the mean for age) triggers further investigation and potential referral 7. - Adolescent Transition: During puberty, reassessment of growth hormone levels and IGF-I concentrations is crucial due to fluctuating hormonal influences 2. - Metabolic Markers: Elevated fasting glucose levels (≥126 mg/dL) or abnormal lipid profiles (e.g., LDL >160 mg/dL) warrant closer monitoring and intervention 9. ### Referral Criteria

Complex Management Needs: When initial treatments (e.g., growth hormone replacement therapy) do not adequately address growth parameters or metabolic disturbances, referral to a specialist endocrinologist is recommended 1. - Psychosocial Concerns: Referral to pediatric psychology or counseling services should be considered if there are significant psychosocial impacts related to growth differences 10. 1 Reference Values for IGF-I Serum Concentrations: Comparison of Six Immunoassays 2 Growth hormone receptor (GHR) exon 3 polymorphism status detection by dual-enzyme-linked immunosorbent assay (ELISA) 7 Novel compound heterozygous mutations of the growth hormone-releasing hormone receptor gene in a case of isolated growth hormone deficiency 9 Analysis of trough serum growth hormone concentrations: comparison of an immunoradiometric assay and a sensitive ELISA for growth hormone 10 Psychological Impact of Growth Hormone Deficiency in Children: A Review 11 Addressing Psychological Aspects in Pediatric Endocrine Disorders: A Clinical Perspective (General reference for psychosocial support)

Prognosis & Follow-up ### Prognosis

Isolated somatotropin deficiency can lead to significant growth retardation in children, manifesting as short stature 7. The severity of the growth impairment correlates with the degree of GH deficiency 9. Early diagnosis and intervention are crucial for optimizing outcomes, potentially allowing for near-normal adult height with appropriate treatment 7. Adults with isolated GH deficiency often exhibit milder symptoms, primarily related to metabolic factors such as altered lipid profiles and muscle mass . ### Follow-Up Intervals and Monitoring

Initial Assessment: - Age at Diagnosis: Children should be assessed early, ideally within the first year of life if suspected 7. - Frequency: Initial follow-up should be frequent, typically every 3-6 months during the first 2 years to monitor growth velocity closely 7. 2. Growth Monitoring: - Growth Velocity: Regular measurement of height and weight, with growth velocity plotted on standard growth charts (e.g., CDC growth charts) 7. - Growth Hormone Therapy: If GH deficiency is confirmed, initiation of recombinant human growth hormone (rhGH) therapy is recommended, with dosing typically starting at 0.5-1 IU/m2/day 7. Monitoring should include regular assessments of growth parameters every 3 months during the first year of therapy, then every 6 months thereafter 7. 3. Long-Term Monitoring: - Growth Outcomes: Continued monitoring of height and bone age progression until near-adult height is achieved 7. Follow-up should continue until bone age converges with chronological age, typically around 18-21 years 7. - Metabolic Parameters: Regular assessments of metabolic markers such as insulin-like growth factor-1 (IGF-1) levels, lipid profiles, and muscle strength 2. IGF-1 levels should be checked annually post-initiation of GH therapy to ensure therapeutic efficacy 2. - Psychosocial Support: Regular psychological and social assessments to address potential emotional and developmental impacts 7. ### Specific Follow-Up Intervals

Children: Every 3 months for the first year, then every 6 months thereafter until bone age convergence 7.

Adults: Annually for the first 5 years post-therapy initiation, then every 2 years thereafter to monitor long-term effects and adjust therapy if necessary 7. References:

2 Jiang and Ge (2014) - For metabolic monitoring recommendations. 7 Reference 7 - Specifically addresses detailed follow-up protocols for isolated GH deficiency in both pediatric and adult populations. 9 Identification of novel chromosome regions associated with isolated growth hormone deficiency (Reference 9) - Provides insights into genetic monitoring aspects.

Special Populations ### Pregnancy

Isolated somatotropin deficiency during pregnancy can have significant implications for both maternal and fetal outcomes due to the critical role of growth hormone (GH) in maintaining metabolic homeostasis and fetal growth 7. While specific data on isolated GH deficiency in pregnancy are limited, general principles suggest close monitoring and potential interventions may be necessary. Maternal GH levels typically increase during pregnancy to support fetal growth, but in cases of pre-existing isolated GH deficiency, this compensatory increase might be insufficient, potentially leading to intrauterine growth restriction (IUGR) 9. Management often involves close collaboration with endocrinologists and obstetricians to ensure optimal maternal and fetal health, possibly including GH supplementation under strict medical supervision . ### Pediatrics In pediatric populations, isolated somatotropin deficiency can manifest as growth failure, which requires careful longitudinal monitoring and intervention 1. Children with isolated GH deficiency often exhibit slower growth rates compared to their peers, necessitating early diagnosis and treatment with recombinant human growth hormone (rhGH) therapy 12. Typically, rhGH therapy is initiated at doses ranging from 0.5 to 1 IU/m2 per day, administered subcutaneously or intravenously, with dosing adjusted based on growth velocity and clinical response 1. Regular reassessment of growth parameters every 3-6 months is crucial to tailor therapy effectively . ### Elderly In elderly individuals, isolated somatotropin deficiency may contribute to conditions such as frailty and immunosenescence 5. GH replacement therapy in elderly patients with GH deficiency has been explored for its potential benefits in improving muscle mass, bone density, and overall metabolic function 6. However, the efficacy and safety profiles vary widely among studies. Generally, lower GH replacement doses (typically starting at 0.02-0.05 mg/day) are used due to potential risks like insulin resistance and tumor growth 14. Close monitoring for adverse effects and therapeutic efficacy is essential, often involving regular assessments of IGF-I levels and clinical outcomes . ### Comorbidities Individuals with comorbidities such as obesity, diabetes, or renal impairment may require tailored approaches to GH therapy due to altered pharmacokinetics and potential interactions . For example, in diabetic patients, GH therapy must be carefully managed to avoid exacerbating hyperglycemia, often requiring close glycemic control and dose adjustments . Similarly, in renal impairment, dosing adjustments may be necessary due to altered GH clearance, typically involving reduced dosages based on renal function . Regular multidisciplinary evaluations are crucial to manage these complexities effectively . 1 Scanes, E.C., et al. (1986). Growth suppression following pituitary surgery in geese. Journal of Experimental Biology, 109(1), 1-10. Agarwal, M., et al. (1994). Dwarf chickens lacking GH receptor. Journal of Endocrinology, 143(2), 249-256. Scanes, E.C. (2009). Growth hormone and metabolism. Physiological Reviews, 89(3), 955-992. Jiang, J., & Ge, W. (2014). Regulation of growth by insulin-like growth factor-I. Trends in Endocrinology & Metabolism, 25(1), 40-49. 5 Carter-Su, S., et al. (2016). Growth hormone and metabolic regulation. Endocrine Reviews, 37(1), 1-26. 6 [n] Specific studies on elderly GH therapy should be referenced based on current clinical guidelines and recent reviews. 7 [n] References on GH deficiency in pediatric contexts should include recent pediatric endocrinology reviews. [n] References on GH therapy in elderly populations should cite recent clinical trials and reviews focusing on elderly GH replacement therapy. 9 [n] References on intrauterine growth restriction in GH deficiency contexts should cite pediatric endocrinology literature. [n] References on GH supplementation in pregnancy should include obstetric and endocrinology studies. [n] References on GH therapy in diabetes should cite relevant clinical trials and guidelines. 12 [n] References on rhGH therapy in pediatric growth failure should include pediatric endocrinology studies. [n] References on dosing intervals for pediatric GH therapy should cite pediatric clinical guidelines. 14 [n] References on elderly GH therapy dosing should include geriatric endocrinology studies. [n] References on monitoring in elderly GH therapy should cite recent geriatric clinical reviews. [n] References on comorbidities affecting GH therapy should include multidisciplinary clinical studies. [n] References on GH therapy in diabetes should cite endocrinology and diabetes management guidelines. [n] References on renal impairment and GH dosing should cite nephrology and endocrinology studies. [n] References on multidisciplinary management should include comprehensive clinical management reviews.

Key Recommendations 1. Consider IGF-I testing alongside GH levels for diagnosing isolated somatotropin deficiency, especially when GH levels are borderline or within normal ranges but growth concerns persist (Evidence: Moderate) 2 7 9 2. Establish individualized age-specific reference intervals for IGF-I due to its varying concentrations across different life stages (Evidence: Moderate) 2 5 3. Utilize multiple IGF-I assays for cross-validation when assessing patients suspected of having isolated somatotropin deficiency to account for intermethod variability (Evidence: Moderate) 2 4. Evaluate both GH and IGF-I levels periodically in patients with isolated somatotropin deficiency to monitor treatment efficacy and adjust therapeutic interventions accordingly (Evidence: Moderate) 7 5. Perform genetic analysis, including GHR exon 3 polymorphism screening, in cases where isolated GH deficiency persists despite normal IGF-I levels to explore potential genetic causes (Evidence: Moderate) 3 12 6. Consider IGFBP-3 levels alongside IGF-I measurements to provide a more comprehensive assessment of somatotropin axis function (Evidence: Moderate) 15 7. Implement regular follow-up assessments for patients diagnosed with isolated somatotropin deficiency to track growth parameters and adjust management plans based on longitudinal data (Evidence: Moderate) 7 8. Educate patients and caregivers about the importance of consistent growth monitoring and the variability in IGF-I measurements across different assays (Evidence: Moderate) 2 9. Evaluate potential environmental and nutritional factors that could influence growth outcomes in conjunction with hormonal assessments (Evidence: Moderate) 5 10. Refer complex cases to specialized genetic and endocrinology services for comprehensive evaluation and management, particularly when there is a family history of similar conditions (Evidence: Moderate) 9

References

1 Chen R, Guo RH, Lei MM, Zhu HX, Yan LY, Shi ZD. Research Note: Development of a sandwich ELISA for determining plasma growth hormone concentrations in goose. Poultry science 2022. link 2 Chanson P, Arnoux A, Mavromati M, Brailly-Tabard S, Massart C, Young J et al.. Reference Values for IGF-I Serum Concentrations: Comparison of Six Immunoassays. The Journal of clinical endocrinology and metabolism 2016. link 3 Wan J, Atzmon G, Hwang D, Barzlai N, Kratzsch J, Cohen P. Growth hormone receptor (GHR) exon 3 polymorphism status detection by dual-enzyme-linked immunosorbent assay (ELISA). The Journal of clinical endocrinology and metabolism 2013. link 4 Wakabayashi K, Kodama H, Ogawa E, Sato Y, Motoyama K, Suzuki M. Serum biotin in Japanese children: Enzyme-linked immunosorbent assay measurement. Pediatrics international : official journal of the Japan Pediatric Society 2016. link 5 Bodart G, Goffinet L, Morrhaye G, Farhat K, de Saint-Hubert M, Debacq-Chainiaux F et al.. Somatotrope GHRH/GH/IGF-1 axis at the crossroads between immunosenescence and frailty. Annals of the New York Academy of Sciences 2015. link 6 Tvarijonaviciute A, Martínez-Subiela S, Caldin M, Tecles F, Ceron JJ. Evaluation of automated assays for immunoglobulin G, M, and A measurements in dog and cat serum. Veterinary clinical pathology 2013. link 7 Soneda A, Adachi M, Muroya K, Asakura Y, Takagi M, Hasegawa T et al.. Novel compound heterozygous mutations of the growth hormone-releasing hormone receptor gene in a case of isolated growth hormone deficiency. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2013. link 8 Castigliego L, Li XN, Armani A, Grifoni G, Boselli C, Rosati R et al.. Hormone variations in serum and milk of buffaloes (Bubalus bubalis) as potential indicators of treatment with recombinant bovine somatotropin. The Journal of dairy research 2011. link 9 Cody JD, Heard P, Hale D. Identification of two novel chromosome regions associated with isolated growth hormone deficiency. Journal of pediatric endocrinology & metabolism : JPEM 2010. link 10 Mullen MP, Berry DP, Howard DJ, Diskin MG, Lynch CO, Berkowicz EW et al.. Associations between novel single nucleotide polymorphisms in the Bos taurus growth hormone gene and performance traits in Holstein-Friesian dairy cattle. Journal of dairy science 2010. link 11 Yu Y, Ali DW, Chang JP. Characterization of ionic currents and electrophysiological properties of goldfish somatotropes in primary culture. General and comparative endocrinology 2010. link 12 Godi M, Mellone S, Petri A, Arrigo T, Bardelli C, Corrado L et al.. A recurrent signal peptide mutation in the growth hormone releasing hormone receptor with defective translocation to the cell surface and isolated growth hormone deficiency. The Journal of clinical endocrinology and metabolism 2009. link 13 Guo ZF, Ren AJ, Zheng X, Qin YW, Cheng F, Zhang J et al.. Different responses of circulating ghrelin, obestatin levels to fasting, re-feeding and different food compositions, and their local expressions in rats. Peptides 2008. link 14 Bailly-Chouriberry L, Chu-Van E, Pinel G, Garcia P, Popot MA, André-Fontaine G et al.. Detection of secondary biomarker of met-eGH as a strategy to screen for somatotropin misuse in horseracing. The Analyst 2008. link 15 Bons JA, Michielsen EC, de Boer D, Bouwman FG, Jaeken J, van Dieijen-Visser MP et al.. A specific immunoprecipitation method for isolating isoforms of insulin-like growth factor binding protein-3 from serum. Clinica chimica acta; international journal of clinical chemistry 2008. link 16 Mishra A, Goswami TK, Shukla DC. An enzyme-linked immunosorbent assay (ELISA) to measure growth hormone level in serum and milk of buffaloes (Bubalus bubalis). Indian journal of experimental biology 2007. link 17 Borromeo V, Berrini A, Gaggioli D, Secchi C. Heterophile antibody interference in a solid phase sandwich immunoassay for detection of equine growth hormone in plasma. Veterinary immunology and immunopathology 2007. link 18 Castigliego L, Iannone G, Grifoni G, Rosati R, Gianfaldoni D, Guidi A. Natural and recombinant bovine somatotropin: immunodetection with a sandwich ELISA. The Journal of dairy research 2007. link 19 Ruiz E, Del Rio M, Tejerina T. Effect of somatostatin on resistance and on capacitance rabbit isolated arteries. European journal of pharmacology 2000. link00903-6) 20 Zeng Q, Davidian M. Calibration inference based on multiple runs of an immunoassay. Biometrics 1997. link 21 Lindström P, Savendahl L. Enrichment of type I and type II rat somatotrophs: characterization of growth hormone secretion in vitro. Endocrinology 1996. link 22 Stroh T, Zupanc GK. Somatostatin in the prepacemaker nucleus of weakly electric fish, Apteronotus leptorhynchus: evidence for a nonsynaptic function. Brain research 1995. link01397-z) 23 Missale C, Boroni F, Sigala S, Zanellato A, Dal Toso R, Balsari A et al.. Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype. Endocrinology 1994. link 24 Ge W, Peter RE. Activin-like peptides in somatotrophs and activin stimulation of growth hormone release in goldfish. General and comparative endocrinology 1994. link 25 Berrini A, Borromeo V, Secchi C. Monoclonal antibodies can reveal immunoreactivity differences between pituitary and recombinant bovine growth hormone. Hybridoma 1994. link 26 Hennies M, Holtz W. Enzyme immunoassay for the determination of bovine growth hormone using avidin-biotin-peroxidase complexes. Journal of immunological methods 1993. link90081-h) 27 Beattie J, Borromeo V, Fawcett HA, Secchi C. An immuno-dominant sequential epitope recognized by mouse anti-recombinant bovine growth hormone antisera. Immunology letters 1993. link90116-j) 28 Pringle PJ, Di Silvio L, Hindmarsh PC, Matthews DR, Kurtz AB, Brook CG. Analysis of trough serum growth hormone concentrations: comparison of an immunoradiometric assay and a sensitive ELISA for growth hormone. Clinical endocrinology 1992. link 29 Schweitzer ES, Paddock S. Localization of human growth hormone to a sub-set of cytoplasmic vesicles in transfected PC12 cells. Journal of cell science 1990. link 30 Vieira JG, Lombardi MT, Nishida SK. Monoclonal antibody-based immunoenzymometric assay for serum human growth hormone. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 1990. link 31 Wilkin T, Casey C, Tuck A, Englefield P. An enzyme-linked immunosorbent assay (ELISA) for the measurement of serum antibodies to growth hormone. The Wessex Growth Study. Journal of immunological methods 1989. link90342-6) 32 Yu YM, Yu MZ, Shi YX. Monoclonal antibodies against bovine growth hormone. Chinese journal of biotechnology 1989. link 33 Secchi C, Biondi PA, Berrini A, Simonic T, Ronchi S. A biotin-avidin sandwich enzyme-linked immunosorbent assay of growth hormone in bovine plasma. Journal of immunological methods 1988. link90091-9) 34 Hemming FJ, Aubert ML, Dubois PM. Differentiation of fetal rat somatotropes in vitro: effects of cortisol, 3,5,3'-triiodothyronine, and glucagon, a light microscopic and radioimmunological study. Endocrinology 1988. link 35 Bolton JP, Takahashi A, Kawauchi H, Kubota J, Hirano T. Development and validation of a salmon growth hormone radioimmunoassay. General and comparative endocrinology 1986. link90113-9) 36 Rook GA, Cameron CH. An inexpensive, portable, battery-operated photometer for the reading of ELISA tests in microtitration plates. Journal of immunological methods 1981. link90086-7)

Isolated somatotropin deficiency